Academic Journal
Rationale for Involved Field Stereotactic Body Radiation Therapy-Enhanced Intermittent Androgen Deprivation Therapy in Hormone-Sensitive Nodal Oligo-Recurrent Prostate Cancer Following Prostate Stereotactic Body Radiation Therapy.
| العنوان: | Rationale for Involved Field Stereotactic Body Radiation Therapy-Enhanced Intermittent Androgen Deprivation Therapy in Hormone-Sensitive Nodal Oligo-Recurrent Prostate Cancer Following Prostate Stereotactic Body Radiation Therapy. |
|---|---|
| المؤلفون: | Carrasquilla, Michael, Creswell, Michael L., Pepin, Abigail N., Wang, Edina, Forsthoefel, Matthew, McGunigal, Mary, Bullock, Elizabeth, Lei, Siyuan, Collins, Brian T., Lischalk, Jonathan W., Esposito, Giuseppe, Aghdam, Nima, Kumar, Deepak, Suy, Simeng, Leger, Paul, Hankins, Ryan A., Dawson, Nancy A., Collins, Sean P. |
| المصدر: | Frontiers in Oncology; 1/18/2021, Vol. 11, pN.PAG-N.PAG, 9p |
| مصطلحات موضوعية: | PROSTATE cancer, RADIOTHERAPY, POSITRON emission tomography |
| مستخلص: | Lymph node recurrent prostate cancer is a common clinical scenario that is likely to increase significantly with the widespread adoption of novel positron emission tomography (PET) agents. Despite increasing evidence that localized therapy is disease modifying, most men with lymph node recurrent prostate cancer receive only systemic therapy with androgen deprivation therapy (ADT). For men who receive localized therapy the intent is often to delay receipt of systemic therapy. Little evidence exists on the optimal combination of local and systemic therapy in this patient population. In this hypothesis generating review, we will outline the rationale and propose a framework for combining involved field SBRT with risk adapted intermittent ADT for hormone sensitive nodal recurrent prostate cancer. In patients with a limited number of nodal metastases, involved field stereotactic body radiation therapy (SBRT) may have a role in eliminating castrate-resistant clones and possibly prolonging the response to intermittent ADT. We hypothesize that in a small percentage of patients, such a treatment approach may lead to long term remission or cure. [ABSTRACT FROM AUTHOR] |
| Copyright of Frontiers in Oncology is the property of Frontiers Media S.A. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| قاعدة البيانات: | Complementary Index |
Full Text Finder | ResultId |
1 |
|---|---|
| Header |
edb Complementary Index 148162822 916 6 Academic Journal academicJournal 915.626831054688 |
| PLink |
https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edb&AN=148162822&custid=s6537998&authtype=sso |
| FullText |
Array
(
[Availability] => 0
)
Array ( [0] => Array ( [Url] => https://resolver.ebscohost.com/openurl?custid=s6537998&groupid=main&authtype=ip,guest&sid=EBSCO:edb&genre=article&issn=2234943X&ISBN=&volume=11&issue=&date=20210118&spage=N.PAG&pages=&title=Frontiers in Oncology&atitle=Rationale%20for%20Involved%20Field%20Stereotactic%20Body%20Radiation%20Therapy-Enhanced%20Intermittent%20Androgen%20Deprivation%20Therapy%20in%20Hormone-Sensitive%20Nodal%20Oligo-Recurrent%20Prostate%20Cancer%20Following%20Prostate%20Stereotactic%20Body%20Radiation%20Therapy.&id=DOI:10.3389/fonc.2020.606260 [Name] => Full Text Finder (s6537998api) [Category] => fullText [Text] => Full Text Finder [Icon] => https://imageserver.ebscohost.com/branding/images/FTF.gif [MouseOverText] => Full Text Finder ) ) |
| Items |
Array
(
[Name] => Title
[Label] => Title
[Group] => Ti
[Data] => Rationale for Involved Field Stereotactic Body Radiation Therapy-Enhanced Intermittent Androgen Deprivation Therapy in Hormone-Sensitive Nodal Oligo-Recurrent Prostate Cancer Following Prostate Stereotactic Body Radiation Therapy.
)
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22Carrasquilla%2C+Michael%22">Carrasquilla, Michael</searchLink><br /><searchLink fieldCode="AR" term="%22Creswell%2C+Michael+L%2E%22">Creswell, Michael L.</searchLink><br /><searchLink fieldCode="AR" term="%22Pepin%2C+Abigail+N%2E%22">Pepin, Abigail N.</searchLink><br /><searchLink fieldCode="AR" term="%22Wang%2C+Edina%22">Wang, Edina</searchLink><br /><searchLink fieldCode="AR" term="%22Forsthoefel%2C+Matthew%22">Forsthoefel, Matthew</searchLink><br /><searchLink fieldCode="AR" term="%22McGunigal%2C+Mary%22">McGunigal, Mary</searchLink><br /><searchLink fieldCode="AR" term="%22Bullock%2C+Elizabeth%22">Bullock, Elizabeth</searchLink><br /><searchLink fieldCode="AR" term="%22Lei%2C+Siyuan%22">Lei, Siyuan</searchLink><br /><searchLink fieldCode="AR" term="%22Collins%2C+Brian+T%2E%22">Collins, Brian T.</searchLink><br /><searchLink fieldCode="AR" term="%22Lischalk%2C+Jonathan+W%2E%22">Lischalk, Jonathan W.</searchLink><br /><searchLink fieldCode="AR" term="%22Esposito%2C+Giuseppe%22">Esposito, Giuseppe</searchLink><br /><searchLink fieldCode="AR" term="%22Aghdam%2C+Nima%22">Aghdam, Nima</searchLink><br /><searchLink fieldCode="AR" term="%22Kumar%2C+Deepak%22">Kumar, Deepak</searchLink><br /><searchLink fieldCode="AR" term="%22Suy%2C+Simeng%22">Suy, Simeng</searchLink><br /><searchLink fieldCode="AR" term="%22Leger%2C+Paul%22">Leger, Paul</searchLink><br /><searchLink fieldCode="AR" term="%22Hankins%2C+Ryan+A%2E%22">Hankins, Ryan A.</searchLink><br /><searchLink fieldCode="AR" term="%22Dawson%2C+Nancy+A%2E%22">Dawson, Nancy A.</searchLink><br /><searchLink fieldCode="AR" term="%22Collins%2C+Sean+P%2E%22">Collins, Sean P.</searchLink> ) Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => Frontiers in Oncology; 1/18/2021, Vol. 11, pN.PAG-N.PAG, 9p ) Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => <searchLink fieldCode="DE" term="%22PROSTATE+cancer%22">PROSTATE cancer</searchLink><br /><searchLink fieldCode="DE" term="%22RADIOTHERAPY%22">RADIOTHERAPY</searchLink><br /><searchLink fieldCode="DE" term="%22POSITRON+emission+tomography%22">POSITRON emission tomography</searchLink> ) Array ( [Name] => Abstract [Label] => Abstract [Group] => Ab [Data] => Lymph node recurrent prostate cancer is a common clinical scenario that is likely to increase significantly with the widespread adoption of novel positron emission tomography (PET) agents. Despite increasing evidence that localized therapy is disease modifying, most men with lymph node recurrent prostate cancer receive only systemic therapy with androgen deprivation therapy (ADT). For men who receive localized therapy the intent is often to delay receipt of systemic therapy. Little evidence exists on the optimal combination of local and systemic therapy in this patient population. In this hypothesis generating review, we will outline the rationale and propose a framework for combining involved field SBRT with risk adapted intermittent ADT for hormone sensitive nodal recurrent prostate cancer. In patients with a limited number of nodal metastases, involved field stereotactic body radiation therapy (SBRT) may have a role in eliminating castrate-resistant clones and possibly prolonging the response to intermittent ADT. We hypothesize that in a small percentage of patients, such a treatment approach may lead to long term remission or cure. [ABSTRACT FROM AUTHOR] ) Array ( [Name] => Abstract [Label] => [Group] => Ab [Data] => <i>Copyright of Frontiers in Oncology is the property of Frontiers Media S.A. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.) ) |
| RecordInfo |
Array
(
[BibEntity] => Array
(
[Identifiers] => Array
(
[0] => Array
(
[Type] => doi
[Value] => 10.3389/fonc.2020.606260
)
)
[Languages] => Array
(
[0] => Array
(
[Code] => eng
[Text] => English
)
)
[PhysicalDescription] => Array
(
[Pagination] => Array
(
[PageCount] => 9
[StartPage] => N.PAG
)
)
[Subjects] => Array
(
[0] => Array
(
[SubjectFull] => PROSTATE cancer
[Type] => general
)
[1] => Array
(
[SubjectFull] => RADIOTHERAPY
[Type] => general
)
[2] => Array
(
[SubjectFull] => POSITRON emission tomography
[Type] => general
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Rationale for Involved Field Stereotactic Body Radiation Therapy-Enhanced Intermittent Androgen Deprivation Therapy in Hormone-Sensitive Nodal Oligo-Recurrent Prostate Cancer Following Prostate Stereotactic Body Radiation Therapy.
[Type] => main
)
)
)
[BibRelationships] => Array
(
[HasContributorRelationships] => Array
(
[0] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Carrasquilla, Michael
)
)
)
[1] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Creswell, Michael L.
)
)
)
[2] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Pepin, Abigail N.
)
)
)
[3] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Wang, Edina
)
)
)
[4] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Forsthoefel, Matthew
)
)
)
[5] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => McGunigal, Mary
)
)
)
[6] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Bullock, Elizabeth
)
)
)
[7] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Lei, Siyuan
)
)
)
[8] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Collins, Brian T.
)
)
)
[9] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Lischalk, Jonathan W.
)
)
)
[10] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Esposito, Giuseppe
)
)
)
[11] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Aghdam, Nima
)
)
)
[12] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Kumar, Deepak
)
)
)
[13] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Suy, Simeng
)
)
)
[14] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Leger, Paul
)
)
)
[15] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Hankins, Ryan A.
)
)
)
[16] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Dawson, Nancy A.
)
)
)
[17] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Collins, Sean P.
)
)
)
)
[IsPartOfRelationships] => Array
(
[0] => Array
(
[BibEntity] => Array
(
[Dates] => Array
(
[0] => Array
(
[D] => 18
[M] => 01
[Text] => 1/18/2021
[Type] => published
[Y] => 2021
)
)
[Identifiers] => Array
(
[0] => Array
(
[Type] => issn-print
[Value] => 2234943X
)
)
[Numbering] => Array
(
[0] => Array
(
[Type] => volume
[Value] => 11
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Frontiers in Oncology
[Type] => main
)
)
)
)
)
)
)
|
| IllustrationInfo |